Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Cancer Discov. 2020 Nov 6;11(2):362–383. doi: 10.1158/2159-8290.CD-20-0455

Figure 2.

Figure 2.

Genotype affects organoid copy number alterations, drug sensitivity, and secretome. A, Shallow WGS (sWGS) of the indicated tumorigenic organoids. Two independent clones are shown for Tp53−/−;Brca1−/−;MycOE and Tp53−/−;Ccne1OE;Akt2OE;KrasOE organoids, respectively, the same Tp53−/−;Pten−/−;Nf1−/− organoid clone at two different times is shown. Copy number losses and gains are shown in blue and red, respectively. B, Dose-response curves for the indicated drugs in tumorigenic organoid lines of different genotypes. Cell viability was calculated relative to 0.01% DMSO-treated control cells, measured after 5 days of treatment. C, Levels of the indicated cytokines, chemokines, and growth factors from 72 hr-conditioned media from the indicated tumorigenic organoids. Only secreted factors that are detectable and differ between groups are shown. Error bars indicate ± SEM; **P<0.01, ***P<0.001, 2-way ANOVA. See also Supplementary Fig. S3.